Dr Ira Klein: Biosimilars and the Cost of Care
Ira Klein, MD, senior director of health care quality strategy for the strategic customer group at Johnson & Johnson Health Care Services, explains how biosimilars will help to control costs.
Transcript:
Do you see biosimilar treatments as playing a role in controlling the cost of care?
I think we’ve already seen biosimilars act as a cost-leveraging mechanism. If you look at the average sales price of original anti—tumor necrosis factor drugs, and you look at the entrance of biosimilars into the marketplace, you can see a definite competitive trend, so there is a lot of competition in this space and that is causing [average sales prices, ASPs] to go down. I think that as the field continues to grow, you’ll see more of this.
I would say that our position is that patients who are on a particular agent should remain on that agent if they’re getting efficacious therapy, because "biosimilar" does not mean "same molecule." For new starts, I think that it should be a level playing field and the competition should be on the basis of both price and service delivery as well as known outcomes. However, I think that on existing therapy, our first duty is to keep the patient safe. But overall, in this field, biosimilars will act in a market force the way other market forces have caused competition to adjust price. We’re seeing that in the marketplace and we think that’s good for the American public.
IGBA 2023: Dr Monique Mansoura Highlights the Intersection of Geopolitical Issues, Biopharma
February 19th 2023COVID-19 allowed governments to critically examine the biopharma space to increase access to vaccines, but there's still a way to go, according to Monique Mansoura, PhD, MBA, executive director of global health security and biotechnology at the MITRE Corporation, at the International Generic and Biosimilar Medicines Association’s annual meeting.
Dr Fran Gregory Sizes Up the US Adalimumab Market: Will Biosimilars See Success?
September 17th 2023On this episode of Not So Different, Fran Gregory, PharmD, MBA, vice president of emerging therapies at Cardinal Health, analyzes the adalimumab market so far in the United States and provides insight into how the market needs to adapt to accept these products and ensure lower drug costs for patients.
Dr Joseph Alvarnas Highlights the Current State of the Oncology Biosimilar Market
November 9th 2022Joseph Alvarnas, MD, vice president of government affairs at City of Hope and chief clinical adviser of AccessHope, explains what the recent FDA approvals of Stimufend and Vegzelma, 2 oncology biosimilars, says about the current state of the oncology biosimilar space.
Expert Opinion: What Factors Will Have the Greatest Impact on US Adoption of Humira Biosimilars?
April 12th 2022Jeffrey Casberg, vice president of pharmacy at IPD Analytics, weighs in on the factors he thinks will most affect market share among adalimumab biosimilars when they enter the US market in 2023.
